GeneBio Systems
Recombinant Human TRAILR1/TNFRSF10A Protein (His Tag)
Recombinant Human TRAILR1/TNFRSF10A Protein (His Tag)
SKU:PKSH031625
Couldn't load pickup availability
Size: 100μg
Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Exp date: 12 months
Category ID_II: Recombinant Proteins
Category ID_III: Others
Abbreviation: TRAILR1/TNFRSF10A
Target Synonym: APO2;CD261;DR4;MGC9365;TNFRSF10A;TRAILR-1;TRAILR1
Research Areas:
Conjugation:
Target Species: Human
Expression Host: HEK293 Cells
Application: Cell culture
Fusion tag: C-His
UNIProt ID:
Accession: NP_003835.2
Background: Tumor necrosis factor receptor superfamily, member 10a (TRAIL R1), also known as TRAIL receptor 1 (TRAIL R1) or CD261 antigen, is a member of the TNF-receptor superfamily. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. TRAIL R1/CD261/TNFRSF10A serves as a receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TRAIL R1 can promote the activation of NF-kappa-B. TRAIL R1/CD261/TNFRSF10A induces apoptosis of many transformed cell lines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types.
Concentration:
Activity: Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L‑929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is typically 50-200 ng/ml in the presence of 20 ng/ml Recombinant Human TRAIL/TNFSF10.
Sequence: Met 1-Asn 239
Purity: > 92 % as determined by reducing SDS-PAGE.
Formulation: Lyophilized from sterile PBS, pH 7.4
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Reconstitution: Please refer to the printed manual for detailed information.
Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
Calculated MW: 15.7 kDa
ObservedMW: 24 kDa
